8-K: Altimmune Reports Q3 2026 Results, Clinical Trials Progress

Altimmune announced third quarter 2026 financial results, detailing progress in its MASH and AUD clinical programs, a robust cash balance, and increased R&D expenses.

Summary

• Altimmune reported its third quarter 2026 financial results and provided a corporate update.
• The company's global PERFORMA Phase 3 trial for MASH is progressing as planned, with topline data anticipated in 2029.
• Positive RECLAIM Phase 2 data for Alcohol Use Disorder (AUD) was presented, and an End-of-Phase 2 meeting with the FDA is scheduled for December 2026.
• Enrollment is complete for the RESTORE Phase 2 trial in Alcohol-Associated Liver Disease (ALD), with topline data expected in the second half of 2027.
• As of September 30, 2026, the company held $480 million in cash, cash equivalents, and investments.
• Research and development expenses increased to $27.0 million for the quarter, compared to $15.0 million in the prior year period, driven by ongoing clinical trials.
• General and administrative expenses rose to $8.7 million from $5.9 million year-over-year.
• The net loss for the quarter was $31.6 million, or $0.15 per share, compared to a net loss of $19.0 million, or $0.21 per share, in the same period of 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting significant clinical trial progress and a strong cash position, though increased R&D spending and a widening net loss are noted.

Positives

• Global PERFORMA Phase 3 trial in MASH is progressing as planned.
• Positive RECLAIM Phase 2 data in AUD was highlighted at AASLD.
• End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026.
• Enrollment complete in RESTORE Phase 2 trial in ALD.
• Company possesses $480 million in cash, cash equivalents, and investments as of September 30, 2026, providing a strong financial runway.
• Pemvidutide has received Breakthrough Therapy Designation for MASH and Fast Track designation for MASH and AUD from the FDA.

Negatives

• Research and development expenses increased to $27.0 million for Q3 2026 from $15.0 million in Q3 2025.
• General and administrative expenses increased to $8.7 million for Q3 2026 from $5.9 million in Q3 2025.
• Net loss for the three months ended September 30, 2026, was $31.6 million, an increase from $19.0 million in the same period of 2025.
• Net loss per share was $0.15 for Q3 2026, compared to $0.21 for Q3 2025.

Risks

• Delays in regulatory review, manufacturing, and supply chain interruptions.
• Challenges in accessing clinical sites and patient enrollment.
• Adverse effects on healthcare systems and disruption of the global economy.
• Reliability of study results concerning human safety and potential adverse effects.
• Company's ability to manufacture clinical trial materials on anticipated timelines.
• Success of future product advancements, including clinical trials.

Future Outlook

The PERFORMA Phase 3 MASH trial topline data readout is anticipated in 2029. Topline data for the RESTORE Phase 2 trial in ALD is expected in the second half of 2027. An End-of-Phase 2 meeting with the FDA for the AUD program is scheduled for December 2026 to discuss a Phase 3 registrational program.

Management Comments

• "We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide," said Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune.
• "Our global PERFORMA Phase 3 trial in MASH is ramping up, and we are very encouraged by the progress to date and the enthusiasm we see from the MASH community."
• "In AUD, we look forward to engaging with the FDA in an End-of-Phase 2 meeting where we will leverage our strong RECLAIM data to discuss a Phase 3 registrational program."
• "Following the recent AASLD meeting, our conviction in pemvidutide's potential is stronger than ever, as we focus on delivering meaningful benefit to patients with serious liver diseases."

Industry Context

StockSavvy.ai notes that Altimmune's focus on MASH, AUD, and ALD aligns with significant unmet medical needs in liver diseases. The company's dual-action agonist, pemvidutide, targets key pathways for these conditions, positioning it within a competitive but high-potential therapeutic area. Progress in Phase 3 trials for MASH and discussions for Phase 3 AUD programs are critical milestones in this space.

Management Changes

Stakeholder Impact

• Shareholders: Increased R&D spending and net loss may impact short-term investor sentiment, while progress in clinical trials offers long-term potential.
• Employees: Continued investment in R&D and corporate growth may lead to increased opportunities and stability.
• Patients: Advancements in clinical trials for MASH, AUD, and ALD offer potential for new therapeutic options.
• Creditors: The company's substantial cash position provides a buffer against short-term financial obligations.

Next Steps

• Continue enrollment and execution of the global PERFORMA Phase 3 MASH trial.
• Engage with the FDA in an End-of-Phase 2 meeting in December 2026 to discuss the Phase 3 registrational program in AUD.
• Receive topline data from the RESTORE Phase 2 trial in ALD in the second half of 2027.
• Anticipate PERFORMA Phase 3 topline data readout in 2029.

Key Dates

Recommendation

The company is making significant progress in its clinical pipeline, particularly with pemvidutide for MASH and AUD, and maintains a strong cash position. However, the increased R&D expenses and widening net loss, coupled with long timelines for Phase 3 data readouts, suggest a 'hold' recommendation pending further de-risking of the clinical programs and clearer commercialization pathways.

Keywords

MASH, pemvidutide, AUD, ALD, clinical trials, Phase 3, Phase 2, biopharmaceutical